Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Tenaya Therapeutics (NASDAQ:TNYA) was given a new $2.00 price target on by analysts at Morgan Stanley.
Tenaya Therapeutics (NASDAQ:TNYA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed [Yahoo! Finance]
Tenaya Therapeutics (NASDAQ:TNYA) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.